Tarek Mousa, MD
Cardiovascular Disease · Astoria, NYNPI 1013177757
Payments from drug & device makers
Across 46 payments — averaging $25.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$301
- Merck$201
- Alnylam Pharmaceuticals Inc.$105
- Kestra Medical Technology Services, Inc.$82
- Medtronic$74
- Lilly USA, LLC$72
- plus $342 from 10 others
What the payments were for
- Food & beverage$1,176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 10 | $301 |
| Merck | 9 | $201 |
| Alnylam Pharmaceuticals Inc. | 4 | $105 |
| Kestra Medical Technology Services, Inc. | 2 | $82 |
| Medtronic | 2 | $74 |
| Lilly USA, LLC | 3 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $70 |
| Novartis | 2 | $49 |
| Boston Scientific | 2 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Medicomp Inc | 2 | $44 |
| Johnson & Johnson | 1 | $22 |
| AstraZeneca | 1 | $19 |
| Abbott | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| Amgen | 1 | $12 |
How this compares
$1,176 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $28,971 |
| Ranolazine ErRanolazine | 161 | $10,790 |
| VascepaIcosapent Ethyl | 17 | $5,049 |
| Rosuvastatin Calcium | 106 | $1,673 |
| Metoprolol Succinate | 87 | $1,506 |
| Atorvastatin Calcium | 118 | $1,393 |
| Amlodipine Besylate | 144 | $966 |
| ClopidogrelClopidogrel Bisulfate | 43 | $775 |
| Losartan Potassium | 78 | $702 |
| Nebivolol Hcl | 16 | $583 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 16 | $535 |
| Lisinopril | 47 | $516 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 36 | $452 |
| Telmisartan | 14 | $308 |
| Pravastatin Sodium | 11 | $260 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Astoria
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.